After a gene therapy setback, Johnson & Johnson agreed to pay $2.2 billion for Ollin and add a retinal disease candidate, according to a BioCentury deal report. The transaction is structured with Blackstone to support Phase III testing, positioning the acquisition as a push to replenish late-stage gene therapy assets after clinical disruption. The deal also reflects how pharma is reallocating capital and timelines toward programs with clearer regulatory and clinical pathways—especially in ophthalmology, where development has historically benefited from measurable endpoints and well-defined trial designs. Market participants will likely watch how J&J integrates the pipeline and whether the retinal candidate can demonstrate differentiation on efficacy and durability relative to existing standards.
Get the Daily Brief